OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessor(s):

THC Farmaceuticals, Inc. The issuer was originally incorporated under the name City Media, Inc. and subsequently changed its name to THC Farmaceuticals, Inc. on February 15, 2015.

2) Address of the issuer's principal executive offices:

Company Headquarters
Address 1: 1000 Newbury Road, Suite 138A
Address 2: Thousand Oaks, CA 91320
Phone: (323)420-8583
Email: info@cbdg.com Website:
https://cbdg.com

IR Contact None

3) Security Information

Trading Symbol: CBDG

Exact title and class of securities outstanding: Common Stock
CUSIP: 177887 106
Par or Stated Value: $0.001
Total shares authorized: 90,000,000 as of: December 31, 2018
Total shares outstanding: 16,631,600 as of: December 31, 2018

Transfer Agent

Action Stock Transfer
2469 E. Fort Union Blvd, Suite 214 Salt
Lake City, UT 84121
Phone: 801-274-1088

Action Stock Transfer is registered under the Exchange Act.

Restrictions on the transfer of security: None

Trading suspension orders issued by the SEC in the past 12 months: None

Stock splits, stock dividends, recapitalizations, mergers, acquisitions, spin-offs, or reorganizations either currently anticipated or that occurred within the past 12 months:

The Company acquired a majority ownership of CBDual Biotechnology Corp. CBDual is a pharmaceutical start-up company focused on developing products based on cannabidiol (CBD). The company facility is located in southern California, providing easy access for patients to participate in clinical trials of new medical cannabis medications, therapies, and products. The Company acquired 50.1% of CBDuals authorized shares in exchange for 1,500,000 CBDG shares and $250,000. The founder of CBDual and owner of the remaining 49.9% of the authorized shares of CBDual will continue to manage the business affairs of CBDual pursuant to a three year employment agreement. If CBDual meets certain benchmarks between now and December 31, 2020, the founder will receive shares of CBDG common stock in exchange for his shares of CBDual stock, whereupon CBDG will own 100% of CBDual. The benchmarks referenced above include achieving certain revenue levels, the filing of patent applications, and the registration with, and subsequent approvals from, the US FDA.

4) Issuance History

Events that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period:

The Company issued 1,500,000 shares for acquiring 50.1% of CBDual Biotechnology Corp.

5) Financial Statements

Incorporated by reference to the financial statements posted with OCT Markets for period ending December 31, 2018

6) Describe the Issuer's Business, Products and Services

A. A description of the issuer's business operations: The Company owns, maintains and places automated teller machines ("ATMs") at high traffic consumer locations in Salt Lake City, Utah and surrounding cities.

B. Date and State of Incorporation: incorporated in the state of Utah on April 14, 2005

C. Issuer's primary and secondary SIC Codes: 2834 and 6199

D. Issuer's fiscal year end date: September 30th

E. Principal products or services, and their markets: Principal products are ATM machines, servicing consumers in the Salt Lake City, Utah area. In addition, on March 10, 2015, the Company filed US patent No. 14-638,939 related to digital currency wallets and specifically to wallets that securely hold multiple currencies. On March 12, 2015, the Company acquired an eighty percent interest in US Patent Application No. 14/564,672 and PCT Application No. PCT/US15/18820, for $8,532. The patents relate to methods of producing antibody-rich cannabis and honeysuckle plants. On January 12, 2017, the Company entered into an agreement with International Construction & Engineering, an Arizona corporation to acquire78 acres of unimproved real property located in Kramer Junction California. Completion of this agreement has not been finalized.

7) Describe the Issuer's Facilities

The Company leases office space in a medical plaza located at 1000 Newbury Road, Suite 138 in Thousand Oaks, California.

8) Officers, Directors, and Control Persons

A. Mike Gravel, CEO
David Tobias, President, Secretary and CFO New Compendium Corp., Controlling Shareholder. Mr. Tobias resigned on January 2, 2018 and Michael Handelman has been retained to be the interim CFO.

B. Legal/Disciplinary History In the last five years, none of the foregoing have been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

C. Beneficial Shareholders. The name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities.

New Compendium Corp
P.O. Box 1363
Discovery Bay, CA 94505
Holder of 63% of the common shares of the issuer.
The controlling shareholder of New Compendium Corp is Sadia Barrameda, P.O. Box 1363 Discovery Bay, CA 94505. The registered agent of New Compendium Corp is Incorp Services, Inc., 36 South 18th Avenue, Suite D, Brighton, CO 80601.

David Tobias
P.O. Box 1236 Islamorada,
FL 33036
Holder of 14% of the common shares of the issuer.

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel

Gary R. Henrie
Gary R. Henrie, Attorney at Law
P.O. Box 107 Nauvoo, IL
62354 Phone: 309-313-
5092
Email: grhlaw@hotmail.com

Accountant

Michael Handelman CPA (inactive)
3210 Rickey Court
Thousand Oaks, CA 91362
Phone: 805-341-2631
Email: mhandelmangroup@gmail.com

Investor Relations Consultant

None

Other Advisor

None

10) Issuer Certification

I, Mike Gravel certify that:

1. I have reviewed this Quarterly Disclosure Statement of THC Farmaceuticals Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

February 25, 2019

/s/ Mike Gravel CEO

THC Farmaceuticals, Inc.
Consolidated Balance Sheets
(unaudited)

	December 31, 2018	September 30, 2018
ASSETS		
Current assets		
Cash	$ 42,454	$ 31,714
Accounts Receivable	1,442	1,442
Deposits and Prepayments	25,000	25,000
Loans Receivable - Related Parties	621,513	621,513
Total current assets	690,409	679,669
Property, Plant and Equipment, net	9,076	9,314
Intangible Assets	1,228,659	1,228,659
Investment in Affiliates	837,050	837,050
Total Assets	$ 2,765,194	$ 2,754,692
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities		
Accounts payable	$ 3,934	$ 2,909
Accrued expenses	29,802	29,802
Accrued interest related parties	577	577
Advances from related parties	48,952	8,952
Note payable - related party	916,724	916,724
Total current liabilities	999,989	958,964
Commitments and Contingencies	-	-
Stockholders' Deficit:		
Preferred stock, par value $0.001, 10,000,000 shares authorized No shares issued and outstanding as of December 31, 2018 and September 30, 2018, respectively	-	-
Common stock, par value $0.001, 90,000,000 shares authorized 16,631,600 and 15,131,600 shares issued and outstanding as of December 31, 2018 and September 30, 2018, respectively	16,631	16,631
Additional paid in capital	3,086,792	3,086,792
Non-controlling interest	(30,231)	(15,000)
Accumulated deficit	(1,307,987)	(1,292,695)
Total Stockholders' Equity	1,765,205	1,795,728
Total Liabilities and Stockholders' Equity	$ 2,765,194	$ 2,754,692

he accompanying notes are an integral part of these consolidated financial statements

THC Farmaceuticals, Inc.
Consolidated Statements of Operations
(unaudited)

	For the Three Months Ended	
	December 31, 2018	**December 31, 201**
Revenue	$ 3,475	$ 3,058
Cost of goods sold	-	-
Gross Profit	3,475	3,058
Operating Expenses:		
General and administrative	33,760	4,724
Depreciation	238	151
Total operating expenses	33,998	4,875
Loss from operations	(30,523)	(1,817)
Other Income (Expense)		
Interest expense	-	-
Total Other (Income) Expense	-	-
Net Income (Loss) Before Income Taxes	(30,523)	(1,817)
Income Tax Expense	-	-
Net Income (Loss)	(30,523)	(1,817)
Loss attributable to non-controlling interest	(15,231)	-
Net Income (Loss) Attributable to THC Farmaceuticals, In	$ (15,292)	$ (1,817)
Net income (loss)		
-Basic	$ (0.01)	$ (0.01)
-Diluted	$ (0.01)	$ (0.01)
Weighted average common shares outstanding		
-Basic	16,631,600	15,131,600
-Diluted	16,631,600	15,131,600

The accompanying notes are an integral part of these consolidated financial statements.

THC Farmaceuticals, Inc.
Consolidated Statements of Stockholders' Equity
(unaudited)

	Common Shares $0.0001 Par Value Shares Issued	Common Shares $0.0001 Par Value Amount	Preferred Shares $0.0001 Par Value Shares Issued	Preferred Shares $0.0001 Par Value Amount	Additional Paid-In Capital	Accumulated Deficit	Non Controlling Interest	Equity (Deficit)
Balance, September 30, 2018	16,631,600	$ 16,631		-	$3,086,792	$(1,292,695)	$ (15,000)	$ 1,795,728
Net loss						(15,292)	(15,231)	$ (30,523)
Balance, December 31, 2018	**16,631,600**	**$ 16,631**	**-**	**-**	**$3,086,792**	**$(1,307,987)**	**$ (30,231)**	**$1,765,205**

The accompanying notes are an integral part of these consolidated financial statements.

THC Farmaceuticals, Inc.
Consolidated Statements of Cash Flows
(unaudited)

	For the Three Months Ended	
	December 31, 2018	December 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income (loss)	$ (30,523)	$ (1,817)
Adjustments to reconcile net income (loss) to net cash used in operating activities:		
Depreciation expense	238	151
Changes in operating liabilities		
Accounts payable	1,025	-
Increase in accounts payable - related parties	-	(334)
Net Cash Used in Operating Activities	(29,260)	(2,000)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Advances from related parties	40,000	2,000
Net Cash Provided by Financing Activities	40,000	2,000
Net Increase in Cash	10,740	-
Cash at Beginning of Period	31,714	-
Cash at End of Period	$ 42,454	$ -
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:		
Cash paid during the year for:		
Interest	$ -	$ -
Income taxes paid	$ -	$ -

The accompanying notes are an integral part of these consolidated financial statements.

THC FARMACEUTICALS, INC
Notes to the Consolidated Financial Statements
For The Three Months Ended December 31, 2018 and 2017 (unaudited)

NOTE 1. Organization and Basis of Operations

City Media, Inc. (the "Company") was incorporated in the state of Utah on April 14, 2005. On September 24, 2010, the Company acquired Charta Systems, Inc. a Utah corporation in a stock exchange reverse acquisition. The acquisition is accounted for as a reverse merger and Charta is considered to be the accounting acquirer. Accordingly, the historical financial information included in the financial statements is that of Charta. During the quarter ended December 31 2014 control of the company was acquired by Weed Growth Fund, Inc. (WEDG) a Nevada corporation in-turn controlled by New Compendium Corporation a Colorado corporation. On February 2015 the Company changed its name to THC Farmaceuticals, Inc. On July 8, 2015 the Company organized Terpene Research Labs, Ltd. under the laws of the state of Colorado as a wholly owned subsidiary.

The Company owns, maintains and places automated teller machines ("ATMs") at high traffic consumer locations in Salt Lake City, Utah and surrounding cities.

With the organization of its subsidiary and the acquisition of certain assets the Company has expanded its business to include the research and development of technologies to facilitate the legal production and sale of hemp, medical marijuana and /or legal recreational marijuana.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue recognition
For revenue from product sales, the Company recognizes revenue using four basic criteria that must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgment regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required.

Basic and Diluted Loss Per Share
The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an "as if converted" basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, there were no outstanding potential common stock equivalents and therefore basic and diluted earnings per share result in the same figure.

Stock-based compensation
The Company adopted FASB guidance on stock based compensation upon inception at November 18, 2013. Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company has not issued any stock or options for services or compensation.

Our employee stock-based compensation awards are accounted for under the fair value method of accounting, as such, we record the related expense based on the more reliable measurement of the services provided, or the fair market value of the stock issued multiplied by the number of shares awarded.

We account for our employee stock options under the fair value method of accounting using a Black-Scholes valuation model to measure stock option expense at the date of grant. We do not backdate, re-price, or grant stock-based awards retroactively. As of the date of this report, we have not issued any stock options.

Fair Value of Financial Instruments
The Company follows the Financial Accounting Standards Board (FASB) Accounting Standards Codification for disclosures about fair value of its financial instruments and to measure the fair value of its financial instruments. The FASB Accounting Standards Codification establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of the fair value hierarchy are described below:

Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.

Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.

Level 3 Pricing inputs that are generally unobservable inputs and not corroborated by market data.

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.

The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

The carrying amounts of the Company's financial assets and liabilities, such as cash, other assets, accounts payable and accrued payroll, approximate their fair values because of the short maturity of these instruments. The carrying values of notes payable and convertible notes approximate their fair values due to the fact that the interest rates on these obligations are based on prevailing market interest rates.

Income Tax Provision
The Company follows the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and

liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date.

The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.

Stock-Based Compensation

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by FASB where the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB where the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Options and warrants granted to non-employees are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the options and warrants vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting. In certain circumstances where there are no future performance requirements by the non-employee, option and warrant grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

The fair value of the Company's stock option and warrant grants are estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or warrants, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model, and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.

Income (Loss) Per Share

Basic income (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income (loss) of the Company. In computing diluted income (loss) per share, the treasury stock method assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and

Derivative Financial Instruments

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through the December 31, 2018 reporting date.

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.

Recently Issued Accounting Pronouncements

There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's consolidated financial position, results of operations or cash flows.

Financial Statement Presentation

The balance sheet presentation herein includes all assets and liabilities at historical cost. No costs for any past project development have been capitalized. Activity of its subsidiary has been consolidated in these statements.

The Company has on occasion issued shares of its common stock in exchange for certain services from the Company's Officers & Directors, business consultants and vendors. The stock has been issued at the fair-valued-based method. The cost of these services has been expensed in the period when the services were performed. No costs of services that were paid with stock have been capitalized.

Fiscal Year

The Company operates on a September 30 fiscal year end.

Cash and Cash Equivalents

For the purpose of the statement of cash flows, cash equivalents include all highly liquid investments with maturity of three months or less.

Accounts Receivable

The Company records an account receivable for revenue earned but not yet collected. If the Company determines any account to be uncollectible based on significant delinquency or other factors, it is immediately written off. The Company has not had to incur any allowance for bad debt as transaction fees are preapproved prior to a transaction.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Dividends

The Company has not yet adopted any policy regarding payment of dividends. No dividends have been paid during the periods reported.

Recent Accounting Guidance

The Company has evaluated the recent accounting pronouncements through ASU 2016-17 and believes that none of the pronouncements will have a material effect on the company's financial statements.

Equipment

The primary nature of the Company's equipment is ATMs. The ATMs are depreciated utilizing a straight line method. The useful life of each machine is approximately twelve years. The remaining useful lives on the machines we are currently utilizing ranges from zero to seven years. The Company has a policy to immediately expense equipment with a cost of less than $400.

Impairment of Long-Lived Assets

The Company reviews the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The estimated future cash flows are based upon, among other things, assumptions about future operating performance, and may differ from actual cash flows. Long-lived assets evaluated for impairment are grouped with other assets to the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. If the sum of the projected undiscounted cash flows (excluding interest) is less than the carrying value of the assets, the assets will be written down to the estimated fair value in the period in which the determination is made. There was zero impairment expense during the period year ended December 31, 2018.

NOTE 3. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company is dependent upon raising additional capital and without realization of such it would be unlikely for the Company to continue as a going concern. The financial statements do not include any adjustments that might result from this uncertainty. As of the date of these statements, management has organized a subsidiary and acquired certain assets to expand its business into the research, development and production of legalized hemp, medical marijuana and /or legal recreational marijuana products. Management plans to continue to seek funding from its shareholders and other qualified investors to pursue its business plan.

NOTE 4. ACQUSITION OF CERTAIN ASSETS

On January 5, 2015, the Company entered into an agreement with the Las Vegas Cannabis Info Center (LVCIC) wherein the Company acquired a thirty percent (30%) interest in LVCIC in exchange for 25,000 common shares and a cash payment of $25,000. LVCIC is a resource and learning center conducting classes in marijuana dispensary management, law, marketing, advertising, cultivation and cooking.

On January 5, 2005, the Company entered into an agreement with a related party to acquire certain intangible assets valued at $1,000,000 thru the issue of 3,000,000 common shares. The assets include the domain name "hempcoin.com;" 2,399,074,298.5 hempcoins (HMP); and all intellectual property associated with hempcoin.com, hempcoin purse, and hempcoin as a crypto currency. The purchase includes all copyrights, trademarks, and patents whether registered or unregistered, statutory or common law and any rights to claim or register such intellectual property.

On March 10, 2015 the Company filed US patent No. 14-638,939 related to digital currency wallets and specifically to wallets that securely hold multiple currencies. No value has been recorded for this asset.

On March 12, 2015, the Company acquired an eighty percent (80%) interest in US Patent Application No. 14/564,672 and PCT Application No. PCT/US15/18820, for $8,532. The patents relate to methods of producing antibody-rich cannabis and honeysuckle plants.

On June 9, 2015, the company entered into an asset Purchase agreement with Rocky Mountain Ayre, Inc., (RMTN) a Delaware corporation. Wherein RMTN agreed to purchase the domain name "hempcoin.com"; 1,500,000,000 hempcoins; and all intellectual property associated with hempcoin.com, hempcoin purse, and hempcoin crypto currency, including copyrights, trademarks, patents etc. The Company received 8,745,000 restricted common shares of RMTN stock which represents approximately Twenty percent (20%) of RMTN outing stock. The agreement includes provisions for the Company to provide annual development costs and server fees of a maximum of $10,000 associated with the promotion of hempcoins.

The Company recorded $787,050 as an investment in affiliates using the equity method for this investment in RMTN. The sale of the 1.5Billion hempcoins leaves the Company with a balance of 899,074,298.5 hempcoins which are included as an intangible asset with a recorded value of $.

During the Quarter ended March 31, 2018 but not finalized until the Quarter ended June 30, 2018 the Company entered into a Rescission Agreement that called for the return of 500,000,000 iCoins previously delivered to RMTN. Further, the Rescission Agreement called for the Company to return to RMTN 7,870,500 of RMTN's restricted common shares reducing the Company's investment in RMTN to approximately 2%. The Rescission resulted in the Company recognizing and extraordinary loss of $589,918.

On September 7, 2018 the Company issued 1,500,000 shares of common stock to acquire a 50.1% equity interest of CBDual Biotechnology Corp.

A summary of Intangible Assets for the period ended December 31, 2018 and the fiscal year ended September 30, 2018 follows:

Intangible Assets:	December 31, 2018	September 30, 2018
Hempcoins	$ 212,950	$ 212,950
Intellectual Property - Patent	8,532	8,532
Goodwill	1,037,000	1,037,000
Less:		
Amortization of goodwill	(29,823)	(29,823)
Total Intangible Assets	$ 1,228,659	$ 1,228,659

A summary of Equity Investments for the period ended December 31, 2018 and the fiscal year ended September 30, 2018 is as follows:

Equity Investment in Affiliates:	December 31, 2018	September 30, 2018
Las Vegas Cannabis Info Center (30%)	$ 50,000	$ 50,000
Rocky Mountain Ayre, Inc. (2%)	78,750	787,050
Total Equity Investments	$ 837,050	$ 837,050

NOTE 5. RELATED PARTY TRANSACTIONS

Service Agreement:

The Company has a Service Agreement with Wasatch ATM ("Wasatch"), a Utah limited liability corporation owned and managed by a Company stockholder. The agreement provides for Wasatch to provide all maintenance, repair and service work along with distribution of vault cash. Currently the agreement provides for a rate of $1,500 per month.

NOTE 6. STOCKHOLDERS' EQUITY

Preferred Stock

The Company is authorized to issue 10,000,000 preferred shares at a par value of $0.001 per share. As of December 31, 2018, no preferred shares are issued and outstanding.

Common Stock

The Company is authorized to issue 90,000,000 common shares at a par value of $0.001 per share. As of December 31, 2018, the Company has a total of 16,631,600 shares of common stock issued and outstanding.

On November 11, 2014 the Company issued 3,003,600 common shares in return for the of all Company debts estimated to be $100,000. Because of the limited activity in the public market the shares were valued at $0.30 per share resulting in the Company recording an $801,080 extraordinary loss.

On January 5, 2015, the Company issued 25,000 common shares and $25,000 to purchase assets valued

at $50,000 accounted for using the equity method. Because of the limited activity in the public marked the shares were recorded using the value of the interest purchased.
On January 5, 2015, the Company issued 3,000,000 common shares to a related party to acquire assets valued at $1,000,000. Because of the limited activity in the public marked the shares were recorded using the value of the interest purchased.

On January 8, 2015, the Company issued 15,000 common shares for consulting services valued at $15,000.

On August 20, 2015, the Company issued 180,000 common shares for consulting services valued at $36,000.

In September, 2018 Company issued 1,500,000 shares for acquiring 50.1% of CBDual Biotechnology Corp.

NOTE 7. PROVISION FOR INCOME TAXES

The Company provides for income taxes under ASC 740 "Income Taxes" which requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect currently.

The standard requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. In the Company's opinion, it is uncertain whether they will generate sufficient taxable income in the future to fully utilize the net deferred tax asset. Accordingly, a valuation allowance equal to the deferred tax asset has been recorded. The total deferred tax asset is $287,757 which is calculated by multiplying a 22% estimated tax rate by the cumulative NOL of $1,307,987 which will began expiring in 2025. The total valuation allowance is a comparable $287,757.

NOTE 8. SUBSIDIARY AGREEMENTS

On September 11, 2015, the Company and its subsidiary Terpene Research Labs, Ltd. (TRL) entered into a development and marketing agreement with Canabis Sativa, Inc. a Nevada corporation (CBDS). Provisions of the agreement include:

a. The development of terpene based products from CBDS' patent pending strain of Cannabis known as CTA.
b. The Company is to receive non-exclusive right to sell terpene products developed by TRL from CBDS' CTA Cannabis for the payment of 10,000,000 hempcoins and a five percent (5%) royalty.
c. CBDG will pay CBDS a thirty-five percent (35%) on all gross revenue received from licensing such terpene products.
d. CBDS shall retain the right to sell products developed by TRL under its "HI" brand and will pay TRL a five percent (5%) royalty on such sales.
e. CBDS shall pay CBDG a thirty-five percent royalty on gross revenue received from CBDS' licensing TRL products to third parties.
f. CBDG shall have the all rights to CTA products developed by TRL for distribution outside North America.

NOTE 9. SUBSEQUENT EVENTS

Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855 after the balance sheet date through the date the financial statements were issued.

The Company did not identify any additional material events or transactions occurring during this subsequent event reporting period that required further recognition or disclosure in these financial statements.